Bristol Myers Squibb Revenue 2010-2022 | BMY
Bristol Myers Squibb annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Bristol Myers Squibb revenue for the quarter ending December 31, 2022 was $11.406B, a 4.83% decline year-over-year.
- Bristol Myers Squibb revenue for the twelve months ending December 31, 2022 was $46.159B, a 0.49% decline year-over-year.
- Bristol Myers Squibb annual revenue for 2022 was $46.159B, a 0.49% decline from 2021.
- Bristol Myers Squibb annual revenue for 2021 was $46.385B, a 9.09% increase from 2020.
- Bristol Myers Squibb annual revenue for 2020 was $42.518B, a 62.62% increase from 2019.
Bristol Myers Squibb Annual Revenue
(Millions of US $) |
| 2022 |
$46,159 |
| 2021 |
$46,385 |
| 2020 |
$42,518 |
| 2019 |
$26,145 |
| 2018 |
$22,561 |
| 2017 |
$20,776 |
| 2016 |
$19,427 |
| 2015 |
$16,560 |
| 2014 |
$15,879 |
| 2013 |
$16,385 |
| 2012 |
$17,621 |
| 2011 |
$21,244 |
| 2010 |
$19,484 |
| 2009 |
$18,808 |
Bristol Myers Squibb Quarterly Revenue
(Millions of US $) |
| 2022-12-31 |
$11,406 |
| 2022-09-30 |
$11,218 |
| 2022-06-30 |
$11,887 |
| 2022-03-31 |
$11,648 |
| 2021-12-31 |
$11,985 |
| 2021-09-30 |
$11,624 |
| 2021-06-30 |
$11,703 |
| 2021-03-31 |
$11,073 |
| 2020-12-31 |
$11,068 |
| 2020-09-30 |
$10,540 |
| 2020-06-30 |
$10,129 |
| 2020-03-31 |
$10,781 |
| 2019-12-31 |
$7,945 |
| 2019-09-30 |
$6,007 |
| 2019-06-30 |
$6,273 |
| 2019-03-31 |
$5,920 |
| 2018-12-31 |
$5,973 |
| 2018-09-30 |
$5,691 |
| 2018-06-30 |
$5,704 |
| 2018-03-31 |
$5,193 |
| 2017-12-31 |
$5,449 |
| 2017-09-30 |
$5,254 |
| 2017-06-30 |
$5,144 |
| 2017-03-31 |
$4,929 |
| 2016-12-31 |
$5,243 |
| 2016-09-30 |
$4,922 |
| 2016-06-30 |
$4,871 |
| 2016-03-31 |
$4,391 |
| 2015-12-31 |
$4,287 |
| 2015-09-30 |
$4,069 |
| 2015-06-30 |
$4,163 |
| 2015-03-31 |
$4,041 |
| 2014-12-31 |
$4,258 |
| 2014-09-30 |
$3,921 |
| 2014-06-30 |
$3,889 |
| 2014-03-31 |
$3,811 |
| 2013-12-31 |
$4,441 |
| 2013-09-30 |
$4,065 |
| 2013-06-30 |
$4,048 |
| 2013-03-31 |
$3,831 |
| 2012-12-31 |
$4,191 |
| 2012-09-30 |
$3,736 |
| 2012-06-30 |
$4,443 |
| 2012-03-31 |
$5,251 |
| 2011-12-31 |
$5,454 |
| 2011-09-30 |
$5,345 |
| 2011-06-30 |
$5,434 |
| 2011-03-31 |
$5,011 |
| 2010-12-31 |
$5,111 |
| 2010-09-30 |
$4,798 |
| 2010-06-30 |
$4,768 |
| 2010-03-31 |
$4,807 |
| 2009-12-31 |
$5,033 |
| 2009-09-30 |
$4,788 |
| 2009-06-30 |
$4,665 |
| 2009-03-31 |
$4,322 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$142.045B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
